Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 50, 2020 - Issue 12
Submit an article Journal homepage
144
Views
0
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Development and validation of a LC-MS/MS method for simultaneous determination of TQ-A3326 and its major metabolites in human plasma, urine and feces: application to pharmacokinetic assay

Bing Xua Department of pharmacy, The Third Hospital of Changsha, Changsha, ChinaView further author information
,
Yang Denga Department of pharmacy, The Third Hospital of Changsha, Changsha, ChinaView further author information
,
Xin Lia Department of pharmacy, The Third Hospital of Changsha, Changsha, ChinaCorrespondence[email protected]
View further author information
,
Siwei Guoa Department of pharmacy, The Third Hospital of Changsha, Changsha, ChinaView further author information
,
Zhenyue Gaob CHIA TAI Tianqing Pharmaceutical Group Co., Ltd, Nanjing, ChinaView further author information
,
Wenyuan Xub CHIA TAI Tianqing Pharmaceutical Group Co., Ltd, Nanjing, ChinaView further author information
,
Yuan Lia Department of pharmacy, The Third Hospital of Changsha, Changsha, ChinaView further author information
,
Ping Zhanga Department of pharmacy, The Third Hospital of Changsha, Changsha, ChinaView further author information
,
Lingling Zhangc XenoBiotic Laboratories, Inc., Nanjing, ChinaView further author information
&
Junchen Huanga Department of pharmacy, The Third Hospital of Changsha, Changsha, ChinaView further author information
 show all
Pages 1451-1460 | Received 20 Apr 2020, Accepted 08 Jun 2020, Published online: 19 Jun 2020

References

  • Abdallah OM, Abdel-Megied AM, Gouda AS. (2018a). Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: application to pharmacokinetic study. Biomed Chromatogr 32:e4186.
  • Abdallah OM, Abdel-Megied AM, Gouda AS. (2018b). Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method. Luminescence 33:1094–100.
  • Anand AC. (2017). Potential liver transplant recipients with hepatitis C: should they be treated before or after transplantation? J Clin Exp Hepatol 7:42–54.
  • Bifano M, Hwang C, Oosterhuis B, et al. (2013). Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 18:931–40.
  • Braman V, Graham P, Cheng C, et al. (2013). A randomized phase i evaluation of CTP-499, a novel deuterium-containing drug candidate for diabetic nephropathy. Clin Pharmacol Drug Dev 2:53–66.
  • Bruggmann P, Berg T, Ovrehus AL, et al. (2014). Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 21:5–33.
  • European Medicines Agency. (2011). Guideline on bioanalytical method validation. Committe for Medicinal Produts for Human Use and European Medicines Agency. Available at: https://doi.org/EMEA/CHMP/EWP/192217/2009
  • European Medicines Agency. (2016). Daklinza (daclatasvir): EU summary of product characteristics. Available at: http://www.ema.europa.eu/ [Accessed 11 Aug 2016].
  • Gandhi Y, Eley T, Fura A, et al. (2018). Daclatasvir: a review of preclinical and clinical pharmacokinetics. ClinPharmacokinet 57:911–28.
  • Hearn BR, Fontaine SD, Pfaff SJ, et al. (2018). Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system. J Control Release 278:74–9.
  • Jiang H, Zeng J, Kandoussi H, et al. (2012). A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine. J Chromatogr A 1245:117–21.
  • Keating GM. (2016). Daclatasvir: a review in chronic hepatitis C. Drugs 76:1381–91.
  • Landis C, Nelson DR, Sulkowski M, et al. (2015). An integrated safety analysis of daclatasvir + sofosbuvir, with or without ribavirin, in patients with chronic HCV infection. Hepatology 62:565A.
  • Messina JP, Humphreys I, Flaxman A, et al. (2015). Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77–87.
  • Nehls C, Buonarati M, Cape S, et al. (2019). GCC consolidated feedback to ICH on the 2019 ICH M10 bioanalytical method validation draft guideline. Bioanalysis 11:1–228.
  • Pharmaceuticals and Medical Devices Agency. (2014). Review Reports: Drugs. Available at: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html#select4
  • Poordad F, Schiff ER, Vierling JM, et al. (2016). Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63:1493–505.
  • Rosenberg ES, Rosenthal EM, Hall EW, et al. (2018). Prevalence of hepatitis C virus infection in US states and the district of columbia, 2013 to 2016. JAMA Netw Open 1:e186371.
  • Spearman CW, Dusheiko GM, Hellard M, et al. (2019). Hepatitis C. Lancet 394:1451–66.
  • Sundaram V, Kowdley KV. (2016). Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 10:13–20.
  • U.S. Food and Drug Administration. (2018). Bioanalytical method validation Guidance for Industry. Available at: https://www.fda.gov/media/70858/download
  • Weiler N, Zeuzem S, Welker MW. (2016). Concise review: interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol 22:9044–56.
  • Zhu X, Wang M, Liu M, et al. (2019). Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med. Available at: https://doi.org/10.2217/pme-2018-0121

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.